Paul Beavis

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.

Kelden Richardson, Simon P Keam, Joe Jiang Zhu, Deborah Meyran, Criselle D'Souza, Sean Macdonald, Kerry Campbell, Michael Robbins, Natalie A Bezman, Kirsten Todd, Hang Quach, David S Ritchie, Simon J Harrison, H Miles Prince, Joseph A Trapani, Misty R Jenkins, Paul A Beavis, Phillip K Darcy, Paul J Neeson

Journal article  |  2023  |  Haematologica

Patients with refractory relapsed multiple myeloma respond to combination treatment with elotuzumab and lenalidomide. The mechanis..

Distinct modulation of IFN gamma-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer

Simon J Hogg, Olga Motorna, Conor J Kearney, Emily B Derrick, Imran G House, Izabela Todorovski, Madison J Kelly, Magnus Zethoven, Kenneth D Bromberg, Albert Lai, Paul A Beavis, Jake Shortt, Ricky W Johnstone, Stephin J Vervoort

Journal article  |  2022  |  CLINICAL EPIGENETICS

BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temp..

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses

Kah Lok Chan, Juliana Gomez, Chelisa Cardinez, Nishi Kumari, Christina E Sparbier, Enid YN Lam, Miriam M Yeung, Sylvain Garciaz, James A Kuzich, Doen Ming Ong, Fiona C Brown, Yih-Chih Chan, Dane Vassiliadis, Elanor N Wainwright, Ali Motazedian, Andrea Gillespie, Katie A Fennell, Junyun Lai, Imran G House, Laura Macpherson, et al.

Journal article  |  2022  |  CANCER CELL

There is increasing recognition of the prognostic significance of tumor cell major histocompatibility complex (MHC) class II expre..

TGFb and CIS Inhibition Overcomes NK-cell Suppression to Restore Antitumor Immunity

Fernando Souza-Fonseca-Guimaraes, Gustavo R Rossi, Laura F Dagley, Momeneh Foroutan, Timothy R McCulloch, Jumana Yousef, Hae-Young Park, Jennifer H Gunter, Paul A Beavis, Cheng-Yu Lin, Soroor Hediyeh-Zadeh, Tania Camilleri, Melissa J Davis, Nicholas D Huntington

Journal article  |  2022  |  CANCER IMMUNOLOGY RESEARCH

Antibodies targeting "immune checkpoints" have revolutionized cancer therapy by reactivating tumor-resident cytotoxic lymphocytes,..

PARP11 interfer(on)es with CAR T cell efficacy

Isabelle Munoz, Paul A Beavis

Journal article  |  2022  |  NATURE CANCER

Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer

Paul A Beavis, Emily B Derrick, Sherene Loi

Journal article  |  2022  |  JOURNAL OF CLINICAL ONCOLOGY

CD4( ) CAR T cells persist long-term CD4( ) chimeric antigen receptor T cells in for the long journey

Amanda XY Chen, Emily B Derrick, Paul A Beavis, Imran G House

Journal article  |  2022  |  IMMUNOLOGY AND CELL BIOLOGY

In a recently published article, Melenhorst et al. performed a longitudinal analysis on chimeric antigen receptor (CAR) T cells is..

Differential location of NKT and MAIT cells within lymphoid tissue

Darryl N Johnson, Zheng Ruan, Emma Petley, Sapna Devi, Lauren E Holz, Adam P Uldrich, Jeffrey YW Mak, Jyh Liang Hor, Scott N Mueller, James McCluskey, David P Fairlie, Phillip K Darcy, Paul A Beavis, William R Heath, Dale Godfrey

Journal article  |  2022  |  SCIENTIFIC REPORTS

Natural Killer T (NKT) cells and Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells that express semi-invariant α..

PTP1B Is an Intracellular Checkpoint that Limits T- cell and CAR T- cell Antitumor Immunity

Florian Wiede, Kun-Hui Lu, Xin Du, Mara N Zeissig, Rachel Xu, Pei Kee Goh, Chrysovalantou E Xirouchaki, Samuel J Hogarth, Spencer Greatorex, Kevin Sek, Roger J Daly, Paul A Beavis, Phillip K Darcy, Nicholas K Tonks, Tony Tiganis

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: Immunotherapies aimed at alleviating the inhibitory constraints on T cells have revolutionized cancer management. To d..

Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells

Kevin Sek, Cheok Weng Chan, Paul A Beavis, Phillip K Darcy

Journal article  |  2021  |  CANCER CELL

In this issue of Cancer Cell, Xue et al. demonstrate that adoptive transfer of tumor-specific Th9 cells can eradicate established ..